TNON

Tenon Medical, Inc. (TNON) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Tenon Medical, Inc. is a medical device company focused on sacro-pelvic disorders, primarily marketing The Catamaran™ SI Joint Fusion System. In August 2025, the Company completed the acquisition of substantially all assets of SiVantage, Inc. (the "SImmetry Acquisition") and SIMPL Medical, LLC (the "SIMPL Acquisition"), adding the SImmetry SI Joint Fusion System to its portfolio. The Company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 32% year-over-year to $1.173 million, driven by an increase in surgical procedures and the inclusion of SImmetry system sales following the August 2025 acquisition. YTD revenue remained relatively flat (-2%) due to lower activity in earlier quarters.
• Margin Expansion: Gross margin improved significantly in Q3 2025 to 66% from 47% in Q3 2024, attributed to operating leverage and increased sales volumes reducing per-unit fixed costs.
• Expense Fluctuations:
  • R&D: Decreased 35% in Q3 and 20% YTD, primarily due to reduced stock-based compensation.
  • Sales & Marketing: Increased 27% in Q3 due to higher commission expenses.
  • G&A: Increased 25% in Q3, largely driven by $0.779 million in acquisition-related costs.
• Balance Sheet: Cash decreased from $6.535 million (Dec 31, 2024) to $3.442 million (Sep 30, 2025). Total liabilities increased to $5.568 million, including $1.011 million in contingent consideration from the SiVantage acquisition.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. Current cash reserves are insufficient to fund operations without additional capital.
• Financing Activities:
  • PIPE Financing: On November 11, 2025, the Company announced a PIPE financing expected to close November 14, 2025, with gross proceeds of $2.85 million via the issuance of common stock and warrants.
  • Equity Issuances: During the nine months ended September 30, 2025, the Company raised approximately $7.067 million through various securities purchase agreements and warrant inducements.
• Acquisition Contingencies: The SiVantage acquisition includes contingent consideration of up to $5.0 million in royalties and potential additional share issuances based on sales milestones ($1M, $10M, and $20M thresholds).
• Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting due to a lack of segregation of duties, though measures are being taken to remediate this.

Investor Verification Checklist

• Liquidity Runway: Verify the closing of the $2.85 million PIPE financing and assess if it extends the cash runway sufficiently beyond the 12-month "going concern" threshold.
• Acquisition Integration: Monitor the realization of synergies from the SiVantage/SIMPL acquisitions and the achievement of sales milestones triggering contingent payments.
• Dilution Impact: Review the total number of outstanding warrants (approx. 5.96 million) and convertible preferred stock to understand potential future dilution.
• Revenue Sustainability: Confirm if the Q3 revenue growth is sustainable or if it was a one-time benefit from the new product line launch.
• Internal Controls: Track progress on remediating the material weakness regarding segregation of duties to ensure future financial reporting reliability.